Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

Malou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, Alphonsus Jm van den Eertwegh, Jules Llm Coenen, Katja Kh Aben, Alphons Cm van den Bergh, Andries M Bergman, Joan van den Bosch, Filiz Celik, Mathijs P Hendriks, Jules Lavalaye, Saskia van der Meer, Marco B Polee, Diederik M Somford, Inge M van Oort, Carin A Uyl-de Groot, Winald R Gerritsen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

Original languageEnglish
Pages (from-to)1371-1384
Number of pages14
JournalFuture Oncology
Volume16
Issue number19
DOIs
Publication statusPublished - Jul 2020

Cite this